A recent study indicates that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise regimens.
Published data in a leading medical journal points out that while overweight individuals can lose substantial amounts of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using such medications must be aware of the potential of fast weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
This pace of recovery means a return to original weight in about one and a half years.
Weighing Approaches
The analysis, which looked at 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.
The team point out that individuals who lose weight through lifestyle changes alone typically see a more gradual creep back—perhaps 100 grams monthly—once they finish.
Understanding the Quick Regain
Nutrition scientists propose the way of the drugs accounts for the accelerated rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal may cause the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication leads to hunger is no longer kept in check, making binge eating much more probable."
A Lifelong Condition?
Health authorities advise the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts say that, considering the likelihood of relapse, the treatment might need to be ongoing.
This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the chronic character of obesity," similar to managing conditions like high blood pressure.
Patient Experiences
Users who have stopped the medication report a intense resurgence of appetite.
"I experienced a trigger flipping and I was suddenly extremely hungry," said one woman.
This challenge is worsened if individuals have not developed sustainable lifestyle or habit changes during treatment.
Growing Interest
Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with interest being substantial.
- Use is more common among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while these medications are powerful tools for weight loss, they are not a permanent solution and maintained weight loss likely depends on integrated behavioural support.
